Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.38 |
| ▸ | PGR | P06401 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2131770 | 0.85 | MRGPRX4 (0.43) | ARCYP11B2CYP11B1MRGPRX4SLC22A12 | |
| SCHEMBL2131444 | 0.84 | CYP11B1 (0.44) | CYP11B2CYP11B1SLC22A12TRPV4 | |
| SCHEMBL23216195 | 0.83 | KDM4E (0.45) | — | |
| SCHEMBL29512405 | 0.83 | KDM4E (0.45) | — | |
| SCHEMBL2136129 | 0.83 | GLA (0.37) | ARCYP11B2CYP11B1MRGPRX4PGR | |
| SCHEMBL2133211 | 0.79 | ALDH1A1 (0.45) | — | |
| SCHEMBL31162985 | 0.79 | MAPT (0.39) | — | |
| SCHEMBL19284539 | 0.79 | HSP90AB1 (0.34) | — | |
| SCHEMBL26091116 | 0.78 | MAOB (0.35) | NSD2NSD3PGR | |
| SCHEMBL16355981 | 0.77 | KDM4E (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445892-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2012-04-26 | — | — | US | disclosed |
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED | 2012-04-26 | — | — | US | disclosed |
| WO-2010148650-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101136-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1- PHOSPHATE RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR3 | AR 1563/4885CYP11B2 427/4885CYP11B1 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.